Nectar Lifesciences Performance
- Today's Low
- ₹11
- Today's High
- ₹12
- 52 Week Low
- ₹9
- 52 Week High
- ₹24
- Open Price₹12
- Previous Close₹12
- Volume128,518
- 50 DMA₹12.04
- 100 DMA₹12.72
- 200 DMA₹14.78
Nectar Lifesciences Chart
Investment Returns
- Over 1 Month -6.93%
- Over 3 Month + 10.98%
- Over 6 Month -43.16%
- Over 1 Year -49.38%
Smart Investing Starts Here Start SIP with Nectar Lifesciences for Steady Growth!
Nectar Lifesciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- -0.9
- PEG Ratio
- 0
- Market Cap Cr
- 256
- P/B Ratio
- 0.4
- Average True Range
- 0.53
- EPS
- 0
- Dividend Yield
- 0
- MACD Signal
- -0.16
- RSI
- 42.34
- MFI
- 44.88
Latest Stock News Updates
Nectar Lifesciences will buyback up to 30 million shares, which represents up to 13.38 per cent of the company's total paid-up equity share capital
- Business Standard
- 6 months 3 weeks ago
Nectar Lifesciences share price hit 52-weel low at 18.6 per share; here's why the stock is under pressure
- Business Standard
- 11 months 2 weeks ago
Nectar Lifesciences Ltd on Tuesday said it will sell its active pharmaceutical ingredients and formulation along with menthol business assets to Ceph Lifesciences Pvt Ltd, for Rs 1,290 crore. The company has signed a definitive Business Transfer Agreement (BTA) for the sale of its core business division, comprising the manufacture, distribution, and marketing of Active Pharmaceutical Ingredients (APIs) and formulations to Ceph Lifesciences for Rs 1,270 crore on a slump sale basis, Nectar said in a regulatory filing. Additionally, the company has entered into an Asset Purchase Agreement (APA) for the sale of its menthol business assets to Ceph Lifesciences for Rs 20 crore, marking a comprehensive restructuring move aligned with its future strategy, it added. "By divesting mature segments of our business, we are laying the foundation for a focused and agile organisation geared towards innovation and long-term value creation," Nectar Lifesciences Promoter and Chairman Sanjiv Goyal...
- Business Standard
- 11 months 2 weeks ago
Nectar Lifesciences Financials
Nectar Lifesciences Technicals
EMA & SMA
- Bearish Moving Average 16
- Bullish Moving Average 0
- 20 Day
- ₹11.80
- 50 Day
- ₹12.00
- 100 Day
- ₹12.70
- 200 Day
- ₹14.80
Resistance and Support
- R3 12.05
- R2 11.90
- R1 11.66
- S1 11.27
- S2 11.12
- S3 10.88
Nectar Lifesciences Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-05-30 | Audited Results | |
| 2026-01-23 | Quarterly Results & Others | To consider other business matters. |
| 2025-11-14 | Quarterly Results | |
| 2025-08-14 | Quarterly Results & Others | To consider other business matters. |
| 2025-07-23 | Others | Inter alia amongst other items, the mode of rewarding of shareholders as contemplated in the explanatory statement to item no. 3 of Notice of 2025-26/01st EGM or matters related thereto. |
About Nectar Lifesciences
- NSE Symbol
- NECLIFE
- BSE Symbol
- 532649
- Chairman & Managing Director
- Mr. Sanjiv Goyal
- ISIN
- INE023H01027
Similar Stocks to Nectar Lifesciences
Popular Stocks
Nectar Lifesciences FAQs
Nectar Lifesciences share price is ₹11 As on 27 June, 2026 | 13:39
The Market Cap of Nectar Lifesciences is ₹256.1 Cr As on 27 June, 2026 | 13:39
The P/E ratio of Nectar Lifesciences is -0.9 As on 27 June, 2026 | 13:39
The PB ratio of Nectar Lifesciences is 0.4 As on 27 June, 2026 | 13:39
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.